Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Assets (2016 - 2025)

Syndax Pharmaceuticals has reported Non-Current Assets over the past 11 years, most recently at $1.6 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $1.6 million for Q4 2025, down 98.67% from a year ago — trailing twelve months through Dec 2025 was $180.0 million (down 28.79% YoY), and the annual figure for FY2025 was $1.6 million, down 98.67%.
  • Non-Current Assets for Q4 2025 was $1.6 million at Syndax Pharmaceuticals, down from $22.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for SNDX hit a ceiling of $121.8 million in Q4 2024 and a floor of $504000.0 in Q2 2021.
  • Median Non-Current Assets over the past 5 years was $16.2 million (2022), compared with a mean of $27.7 million.
  • Biggest five-year swings in Non-Current Assets: soared 2707.54% in 2022 and later tumbled 98.67% in 2025.
  • Syndax Pharmaceuticals' Non-Current Assets stood at $1.3 million in 2021, then soared by 490.8% to $7.4 million in 2022, then soared by 329.58% to $32.0 million in 2023, then surged by 280.45% to $121.8 million in 2024, then tumbled by 98.67% to $1.6 million in 2025.
  • The last three reported values for Non-Current Assets were $1.6 million (Q4 2025), $22.0 million (Q3 2025), and $64.5 million (Q2 2025) per Business Quant data.